论文部分内容阅读
目的观察瑞舒伐他汀对介入治疗冠心病慢性心力衰竭患者预后的影响。方法选取2012年1月—2014年3月心内科收治的78例行介入治疗的冠心病慢性心力衰竭患者,采用随机抽签法均分为对照组和观察组,对照组39例患者行常规基础治疗,观察组39例在常规治疗基础上采用瑞舒伐他汀治疗,两组疗程均为6个月。观察治疗前后两组血脂[胆固醇(TC)、三酰甘油(TG)、高密度脂蛋白(HDL-C)、低密度脂蛋白(LDL-C)]变化情况;以及两组患者心率(HR)、左心室内压(LVP)和左心室射血分数(LVEP)变化情况。结果治疗后两组患者TC、TG、HDL-C较治疗前明显降低,HDL-C较治疗前明显升高,观察组TC(3.24±0.5)mmol/L、TG(1.15±0.32)mmol/L、LDL-C(2.18±0.62)mmol/L比对照组下降显著,HDL-C(2.31±0.32)mmol/L较对照组明显升高,差异具有统计学意义(P<0.05)。治疗后两组HR、LVP均比治疗前小,LVEP明显高于治疗前,差异有统计学意义(P<0.05)。治疗后观察组HR(64.88±4.68)次/min、LVP(9.88±0.79)mm Hg均比对照组下降显著,LVEP(2.31±0.32)分明显高于对照组,差异有统计学意义(P<0.05)。结论瑞舒伐他汀能够改善慢性心力衰竭患者的心功能及血脂水平,可以作为冠心病慢性心力衰竭患者预后的首选药物。
Objective To observe the effect of rosuvastatin on the prognosis of patients with chronic heart failure undergoing coronary intervention. Methods From January 2012 to March 2014, 78 patients with CHD treated with interventional therapy were randomly divided into control group and observation group. 39 patients in control group underwent routine basic treatment , 39 cases in the observation group were treated with rosuvastatin on the basis of routine treatment, and the two courses of treatment were 6 months. The changes of blood lipid (TC, triglyceride, HDL-C and LDL-C) in both groups were observed before and after treatment. Heart rate (HR) , Left ventricular pressure (LVP) and left ventricular ejection fraction (LVEP) changes. Results After treatment, the levels of TC, TG and HDL-C in the two groups were significantly lower than those before treatment, while the levels of HDL-C in the two groups were significantly higher than those before treatment (TC, 3.24 ± 0.5 mmol / L and TG 1.15 ± 0.32 mmol / L, (2.18 ± 0.62) mmol / L, while HDL-C (2.31 ± 0.32) mmol / L was significantly higher than that of the control group. The difference was statistically significant (P <0.05). After treatment, HR and LVP in both groups were smaller than those before treatment, LVEP was significantly higher than before treatment, the difference was statistically significant (P <0.05). After treatment, HR (64.88 ± 4.68) / min and LVP (9.8 ± 0.79) mm Hg in the observation group decreased significantly compared with the control group, LVEP (2.31 ± 0.32) was significantly higher than that of the control group, the difference was statistically significant (P < 0.05). Conclusion Rosuvastatin can improve the heart function and blood lipids in patients with chronic heart failure and can be used as the drug of choice for the prognosis of patients with chronic heart failure of coronary heart disease.